Journal of Nuclear Medicine Technology · 2016 · 12 citations · 24 references
MedicineOncologyPathologyGastrointestinal OncologyNeoplasiaTumor PathologyCancer MetabolismCancer Molecular PathologyGastric CancerMalignant NeoplasmsTumor CharacterizationTumor ImagingGastrointestinal MalignancyGastrointestinal TumorsHer2 ExpressionMolecular Prognostic MarkersOncologic Pet ImagingPathology Of Gastric CancerPathology ReportsTumor Aggressiveness Assessment
The human epidermal growth factor 2 (HER2)–overexpressing (HER2-positive [HER2+]) gastric (GC) and gastroesophageal junction adenocarcinomas (GEJC) are felt to represent a more aggressive form of disease, which may correlate to increased metabolic activity. Whether tumor SUV<sub>max</sub> measured by <sup>18</sup>F-FDG PET/CT could be a preoperative parameter used to predict HER2 status of GC/GEJC is unknown. <b>Methods:</b> Pathology reports of HER2+ GC/GEJC biopsies and resections from 31 patients were reviewed and compared with HER2-negative (HER2−) cases distributed evenly over the same time period. We analyzed their SUV<sub>max</sub> intensity and then compared the HER2 status and SUV<sub>max</sub> parameters and their association with survival. <b>Results:</b> After matching for age and sex, there was no difference in SUV<sub>max</sub> between HER2+ and HER2− cases (9.7 and 8.4, respectively; <i>P</i> = 0.6). No difference was seen between HER2+ and HER2− cases in tumor histology (81% and 57% intestinal type, respectively; <i>P</i> = 0.11), size (2.6 and 3.8 cm, respectively; <i>P</i> = 0.12), differentiation (47% and 68% poorly differentiated, respectively; <i>P</i> = 0.06), or presence of lymph node metastasis (60% and 40%, respectively; <i>P</i> = 0.3). Although there was no difference in survival demonstrated by HER2+ and HER2− cases, there was a significant difference in survival between SUV<sub>max</sub> above (12.2 mo) and below (30 mo) the median SUV<sub>max</sub> (6.6, <i>P</i> = 0.01). <b>Conclusion:</b> Our study shows that SUV<sub>max</sub> is not associated with HER2 status of GC/GEJC. Independent of HER2 overexpression, patients with a high SUV<sub>max</sub> demonstrate a worse overall survival, suggesting that metabolic signature is a better predictor of biologic tumor aggressiveness than its histologic signature.
24
Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text
Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Manfred Hofmann, Di Shi, Reinhard Büttner et al. · Histopathology · 2008 · 1.2K citations
Medicine, Oncology, Fish Pathology +16
Recommendations on the Use of <sup>18</sup>F-FDG PET in Oncology
James Fletcher, Benjamin Djulbegović, Heloisa P. Soares et al. · Journal of Nuclear Medicine · 2008 · 1.1K citations · Full text
Medicine, Oncology, Cancer Screening +14
HER2 testing in gastric cancer: a practical approach
Josef Rüschoff, Wedad Hanna, Michael Bilous et al. · Modern Pathology · 2012 · 596 citations · Full text